Signed in as:
filler@godaddy.com
Our Approach to Treat a Range of Aggressive Cancers
At iPSirius, we are developing active immunotherapies based on Induced Pluripotent Stem Cells (iPSC) that presents a new avenue for treating a variety of late stage cancers with a stemness signature including non-small cell lung cancer, glioblastoma, triple negative breast cancer and pancreatic cancer.
Our products can be administered as single agent or in combination with other therapies to enhance anti-tumor immunity improving prognoses and therapeutic options for patients. Our strategy encompasses the prevention and management of tumor relapse and metastasis. This is achieved through precise targeting of an innovative class of cancer-associated antigens.